Anabron

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anabron

Quick Facts

Feature Detail
Active Ingredient Ambroxol Hydrochloride
Drug Class Mucolytic Agent
Availability Often Over-the-Counter (OTC) or Prescription (Rx) depending on country/form
Primary Use Respiratory diseases with excessive, thick mucus production

Anabron is a brand name for a medication whose active ingredient is Ambroxol Hydrochloride (INN). It belongs to the mucolytic class of drugs, which are specifically designed to treat respiratory conditions where the airways are clogged by abnormal or excessive amounts of viscous mucus.

Ambroxol is characterized by a mechanism of action that goes beyond simply thinning mucus. It functions as a secretolytic agent, which aids in liquefying secretions, and a secretomotoric agent, which promotes the clearance of mucus from the airways. This dual action facilitates the synthesis and release of pulmonary surfactant, a substance critical for reducing the stickiness of mucus and improving its transport.

While the specific dosage forms and availability of the Anabron brand may vary by country and manufacturer, its core ingredient, Ambroxol, is commonly available worldwide as tablets, capsules, and oral solutions (syrups). Popular international brand names containing the same active ingredient include Lasolvan and Mucosolvan. Ambroxol’s utility is also differentiated by its local anesthetic effect, which makes certain formulations, like lozenges, a common choice for providing relief from sore throat pain.

It is indicated for secretolytic therapy in various bronchopulmonary diseases, such as acute and chronic bronchitis, bronchiectasis, and other conditions involving impaired mucus transport.

What side effects are possible with Anabron?

Possible Side Effects and Safety Information

The safety profile for Anabron, which contains Ambroxol Hydrochloride, is based on official classifications from government regulatory documents, detailing possible adverse reactions and required safety precautions.

Adverse effects are documented and categorized by frequency and the System-Organ-Class (SOC) affected.

Officially Classified Adverse Reactions

Reactions classified as Common (affecting up to 1 in 10 patients) primarily involve the gastrointestinal system and sensory functions, including nausea, diarrhoea, dysgeusia (altered taste), oral hypoesthesia (numbness of the mouth), and pharyngeal hypoesthesia (numbness of the throat).

Uncommon reactions (affecting up to 1 in 100 patients) include vomiting, abdominal pain, dyspepsia, dry mouth, and fever.

Serious Safety Considerations

The regulatory profile documents rare but serious adverse reactions, particularly those related to the immune system and skin. These include hypersensitivity reactions (Rare) and, with a frequency classified as Not Known, severe reactions such as anaphylactic shock, angioedema, and Severe Cutaneous Adverse Reactions (SCARs), which encompass Stevens-Johnson syndrome/Toxic epidermal necrolysis (SJS/TEN).

Safety Constraints and Population-Specific Cautions

Official labeling defines specific conditions that require caution:

  • Renal and Hepatic Impairment: Caution is necessary in patients with renal impairment or severe hepatic impairment due to the potential for metabolite accumulation.
  • Ulcers and Airway Motility: Caution is advised for patients with a history of peptic or duodenal ulcers and those with compromised airway motility.
  • Drug Interactions: Co-administration with antitussives (cough suppressants) should be avoided due to the potential for congestion of bronchial secretions.
  • Pregnancy: The medication is not recommended during the first trimester of pregnancy.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation describes the overdose profile of Anabron (Ambroxol Hydrochloride) as having a low inherent risk for severe, life-threatening outcomes, with no serious sequelae observed in typical cases. The signs of overdose are primarily an extension of the known undesirable effects, consistent with regulatory classification of minimal severe toxicity.

Documented Overdose Manifestations Overdose may present with gastrointestinal disturbances, including nausea, vomiting, diarrhea, and dyspepsia (indigestion). Other reported signs of high exposure include short-term anxiety and excessive saliva secretion. Though rare, the potential for severe poisoning effects is cautioned against only following a very high overdose.

Required Emergency Actions Regulatory instructions are clear: if the recommended dosage is exceeded, individuals are mandated to consult a doctor or go to the hospital for immediate assessment. No specific antidote is known for Anabron, and treatment is strictly symptomatic and supportive. The patient should be observed following the institution of supportive care. Procedures such as gastric lavage are described, but reserved for cases of very high overdose within two hours of ingestion. The profile also notes that metabolite accumulation is expected in patients with severe renal insufficiency.

Therapeutic Uses of Anabron

What Anabron Treats: Main Uses and Benefits

Anabron, containing ambroxol, is commonly used to help with symptoms related to thick, sticky secretions that interfere with breathing and airway clearance. The core therapeutic focus is applied across domains where additional symptomatic support is needed for acute and chronic conditions characterized by periods of heightened symptoms.

Specifically, the medication is generally used for managing symptoms in conditions such as bronchitis, pneumonia, bronchiectasis, and certain long-term lung disorders. By addressing these secretions, it provides support that helps ease the overall symptom burden and may assist with maintaining functional stability during periods of heightened symptoms.

The therapeutic approach is aligned with supportive symptom management, which is relevant for managing symptoms that interfere with daily comfort. In a separate therapeutic domain, the medication is considered relevant for use in situations involving certain distressing symptoms related to inflammatory or irritative states, specifically to address pain associated with acute sore throat (pharyngitis).


Quick Fact: Relief for Symptomatic Discomfort Symptom Targeted Primary Benefit
Thick, sticky mucus Contributes to easing the functional strain associated with clearing secretions.
Acute sore throat pain Is applied in addressing symptoms related to inflammatory or irritative states.
Airway congestion Supports general well-being during symptomatic phases.

Regulatory References

  1. European Medicines Agency guidance on ambroxol

Eligibility and Restrictions for Use

Official Eligibility Rules for Anabron

Anabron (Ambroxol Hydrochloride) eligibility is strictly defined by regulatory documents, which stipulate populations who may use the medicine, those who are restricted, and those who must not use it.

Absolute Contraindications

Population Group Restriction Status
Hypersensitivity Contraindicated in patients with known allergy to Ambroxol or its excipients.
Infants Contraindicated for use in children under 2 years of age in most regulatory labels.
Hereditary Intolerance Contraindicated for patients with rare hereditary fructose intolerance (applies to certain liquid forms).

Restricted and Conditional Use

Use of Anabron is officially limited and requires caution for certain populations due to potential risks or altered metabolism:

  • Pregnancy and Lactation: Use is not recommended during the first trimester of pregnancy and is also not recommended for women who are breastfeeding.
  • Organ Impairment: Patients with severe hepatic (liver) or renal (kidney) impairment must use the medicine with caution, often requiring specific administration adjustments.
  • Comorbidities: Caution is required for individuals with a history of peptic ulcers or conditions involving compromised airways, such as primary ciliary dyskinesia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Anabron (Ambroxol Hydrochloride) is defined by officially documented restrictions and pharmacokinetic cautions, with regulatory labels generally indicating a low risk for unfavorable systemic drug-drug interactions.

Interaction Scope and Restrictions

Category Official Regulatory Documentation
Interacting product categories Antitussive medications (cough suppressants) and certain Antibiotics (e.g., macrolides, beta-lactams).
Interaction-related restrictions Co-administration with antitussive agents is advised against due to the pharmacodynamic restriction of potentially suppressing the cough reflex, which may interfere with the clearance of liquefied bronchial secretions.

Official Interaction Statements

  • Pharmacodynamic Enhancement: Co-administration with certain antibiotics, including Amoxicillin, Cefuroxime, Erythromycin, and Doxycycline, results in an increase in the antibiotic concentration within bronchopulmonary secretions and lung tissues.
  • Exposure in Hepatic and Renal Impairment: Official cautions are issued regarding potential exposure-modifying effects in specific populations. In patients with hepatic dysfunction, the clearance of ambroxol is decreased, leading to plasma levels that may be approximately 1.3 to 2 times higher. A risk of accumulation of ambroxol metabolites is noted in cases of severe renal insufficiency.

No mandatory timing or separation requirements are stated in the official prescribing information, and no specific interactions with food, alcohol, or herbal products are consistently documented.

Mechanism of Action

How Anabron Works

Dual Action: Modulating Secretion Quality and Clearance Dynamics

The molecule functions as both a secretolytic and a secretomotoric agent. It stimulates Type II pneumocytes to increase the synthesis and release of pulmonary surfactant. Surfactant integrates into the mucus layer, reducing its viscosity and adhesiveness. Concurrently, it stimulates the bronchial cilia to increase their beat frequency. This combination of liquefied secretions and accelerated ciliary movement results in an enhanced mucociliary transport rate.


Local Anesthetic Action via Nerve Signaling Inhibition

A distinct pharmacological domain involves the compound's effect on peripheral sensory nerve fibers. This action is mediated by the non-selective blockade of voltage-gated sodium channels ( Na v channels) within the nerve cell membrane. By preventing the influx of sodium ions, it stabilizes the nerve membrane and inhibits the generation and transmission of the signal for nociception, resulting in a temporary, localized absence of nerve excitability.


Adjunctive Anti-inflammatory and Antioxidant Modulation

Beyond its core actions, the molecule exhibits pleiotropic properties by modulating local tissue stress mechanisms. It acts as an antioxidant by scavenging Reactive Oxygen Species (ROS) and modulates local inflammatory pathways by reducing the release of pro-inflammatory mediators. This mechanism affects the cellular environment within the respiratory mucosa.

Dosage and Administration Information

How Anabron is Used: Administration Guidelines

Administration of Anabron (Ambroxol Hydrochloride) follows established dosing schedules. These instructions define the method, timing, and duration of use.

Feature Instruction Summary
Approved Routes Primarily Oral (tablets, syrups, sustained-release capsules). Intravenous (IV), Intramuscular (IM), and Inhalation forms are also used for specific clinical and hospital-based contexts.
Standard Adult Dosing The typical regimen for immediate-release forms begins with an initial dose of 30 mg, three times daily (90 mg total daily dose), for the first 2–3 days. Treatment is then commonly continued with 30 mg, twice daily (60 mg total daily dose). The total daily dose may be increased up to 120 mg if necessary.
Sustained-Release (SR) Dosing The 75 mg SR capsule is administered once daily to provide a sustained-release profile.
Timing and Intake Oral formulations should be taken with or after a meal. Adequate fluid intake is recommended alongside administration.
Handling & Preparation SR capsules must be swallowed whole and must not be crushed or chewed. Effervescent tablets can be divided into equal doses.

Duration and Special Population Rules

For acute, short-term symptomatic use, the medication should not be taken for more than 4 to 5 days without seeking medical advice. Dose adjustments for specific populations are utilized where appropriate. For pediatric patients, age-specific regimens using drops or syrup are used. In cases of severe hepatic or renal impairment, the dose is administered with caution, potentially requiring reduction or longer time intervals, as metabolites may accumulate. No special dose adjustment is required for older adults.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Anabron (Ambroxol)

Evidence for Use in Acute and Chronic Respiratory Diseases

Research has examined Anabron (ambroxol) in research contexts involving the symptoms of excessive, thick mucus in conditions characterized by fluctuating or episodic manifestations. The evidence base primarily includes Randomized Controlled Trials (RCTs) and systematic reviews that was evaluated in comparison to a placebo or to other supportive therapies. Studies monitored patient-reported outcomes describing perceived discomfort, such as how easy it was for participants to cough up phlegm, and the reported intensity of their cough.

Studies report how symptoms evolved in the observed populations over the short-term observation periods. However, research into more objective outcomes reflecting daily functioning or activity level, such as detailed lung function measurements, often data show patterns related to inconsistent results across the diverse study groups. The evidence quality varies across studies, particularly with older trials lacking modern methodological rigor.


Evidence for Use in Symptomatic Sore Throat Relief

Research examining Anabron for sore throat relief was evaluated in short-term trials that used an inactive comparison substance that was studied for outcomes linked to inflammatory or irritative states of the throat. These studies specifically examined lozenge or spray formulations. Researchers monitored outcomes related to physical discomfort, tracking how rapidly and to what degree participants reported pain intensity over the initial hours of treatment.

Trials applied in studies examining patient-reported experiences data show patterns related to pain intensity measurements when comparing ambroxol-containing lozenges to the placebo lozenges. These short-term studies contribute to understanding symptom patterns and help contextualize how patients reported their experience during this acute, brief period.


What Is Still Uncertain About Anabron Research

Follow-up durations were limited in many primary studies, meaning there is limited information for long-term outcomes that could describe sustained efficacy or changes in the disease course over many years. Also, some major regulatory reviews have noted that evidence is limited to establish the drug's efficacy for secretolytic therapy in children under 6 years of age. Research does not determine whether an individual will respond similarly and findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Anabron (FAQ)


Q: Are there different strengths or forms of Anabron available?

Yes, Anabron, which contains the active ingredient Ambroxol, is available in multiple forms depending on the country and manufacturer. These forms include immediate-release tablets, syrups, and sustained-release capsules. Specialty forms like drops and effervescent tablets are also listed in regulatory documents as available preparations, with the strength of the active ingredient varying across these preparations.


Q: How quickly can someone generally expect to feel the effects of Anabron?

Official drug information suggests that the secretolytic (mucus-thinning) action typically begins quickly after taking the oral forms of the medication. This onset of action is generally documented to occur within approximately 30 minutes following administration.


Q: If I miss a scheduled time to take Anabron, what is the general guidance?

General patient guidance advises that if a dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule should be continued, rather than taking two doses at once.


Q: Can Anabron be taken with alcohol?

The official regulatory documents covering the active ingredient in Anabron do not consistently document any specific interaction or restriction for taking the medication with alcohol. Any patient concerns about alcohol consumption are best discussed with a healthcare professional.


Q: Can Anabron be used by children, and if so, at what age?

The medicine is generally contraindicated, or not suitable for use, in children under 2 years of age according to most regulatory labels. Specific, age-appropriate dosing regimens are officially detailed for children between 2 and 12 years in the prescribing information, which should be consulted for use in this population.


Q: What information is available regarding Anabron use during pregnancy?

Official eligibility rules advise that the medicine is not recommended during the first trimester of pregnancy. For the second and third trimesters, clinical experience has generally shown no evidence of harmful effects on the foetus. Official regulatory information advises that the usual precautions regarding medication use during pregnancy should still be observed.


Q: Can Anabron be taken if I am breastfeeding?

Official product information advises that the medicine is not recommended for women who are breastfeeding, citing studies in animals indicating that the active ingredient may be excreted into breast milk.


Q: Are there any specific vitamins or supplements that are known to interact with Anabron?

Official regulatory documents define interactions primarily with antitussive agents and certain antibiotics. The general interaction statements do not consistently document specific interactions with vitamins or common mineral supplements.


Q: Does Anabron interact with herbal remedies like St. John's Wort?

The official product information and interaction statements indicate that no specific, problematic interactions with herbal products are consistently documented.


Q: What is the maximum duration of time Anabron is usually prescribed for?

For acute, short-term symptomatic use, official labeling specifies the medication should not be taken for more than 4 to 5 days without seeking medical advice. For chronic conditions, official research and clinical observation studies have examined the use of the medicine over longer periods, such as up to 6 months, depending on the prescribing context.


Q: Does Anabron cause tiredness or affect my ability to drive?

Based on the documented safety profile, official regulatory documents state the medicine has no or only a negligible influence on the ability to drive or operate machinery. This conclusion is drawn from the known profile of the medication, as dedicated driving studies have not been performed. Any perceived side effect is best discussed with a healthcare provider.


Q: What are the known potential severe or serious side effects of Anabron?

Regulatory safety information documents rare but serious adverse reactions. These include hypersensitivity reactions, anaphylactic shock, angioedema, and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome/Toxic epidermal necrolysis. These types of reactions are documented as conditions that may require immediate medical evaluation.


Q: Is Anabron a type of antibiotic?

No, Anabron is not an antibiotic. The active ingredient, Ambroxol, is officially classified as a mucolytic agent. It is intended to help the body clear mucus and is sometimes used alongside antibiotic treatment for respiratory infections.


Q: What is the distinction between the main uses and other reported benefits of Anabron?

The medicine’s primary classification is as a mucolytic agent intended to enhance mucus clearance in respiratory conditions. A separate and distinct function noted in pharmacological studies is a local anesthetic action, which is utilized in certain dosage forms to provide symptomatic relief from pain, such as a sore throat.


Q: Is it true that Anabron is not effective for everyone?

Official research findings describe the patterns and responses observed across groups of participants in clinical trials. Regulatory documents state that these findings do not determine whether a specific individual will experience similar results, which suggests that individual responses to the medication may vary.


Q: How long does Anabron typically stay in the body after the last use?

Pharmacokinetic data in regulatory documents indicate that the terminal elimination half-life of the active ingredient is approximately 10 hours. This measure describes the time required for the concentration of the substance in the body to fall by half.

How should Anabron be stored and disposed of?

Storage Requirements

Official regulatory documents define the storage constraints for Anabron (Ambroxol Hydrochloride) to maintain product stability. The medicine must be stored at a temperature not exceeding 30 C and protected from light. It is mandatory to keep the product in its original container, tightly closed, and stored in a dry place.

For liquid forms such as oral solutions, the official stability is limited; the product must be discarded one month after first opening the bottle, regardless of the printed expiration date.

Disposal and Child Safety

All medicines must be stored out of the sight and reach of children (often specified as 'Store locked up') to prevent accidental access. Disposal must follow local, regional, and national regulations. Due to the active ingredient's documented toxicity to aquatic life, it is explicitly prohibited to dispose of the product by throwing it into wastewater or releasing it to the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anabron found in:

A-Z Index: